A new Nature study of 15,000 people reveals that genetic variants influence how much weight individuals lose on drugs like Wegovy and Mounjaro, but the variants are far more common in people of European ancestry, raising questions about who truly benefits.
Genetic differences explain a significant part of why weight-loss drugs like Wegovy and Mounjaro produce wildly uneven results — some users lose 10–15% of their body weight, while others on the same drug at the same dose lose as little as 2–3%, according to BBC Health reporting on emerging research. That gap isn't noise. It's a signal that the era of prescribing these blockbuster drugs as one-size-fits-all is already outdated — and that personalized medicine needs to catch up.
The prevailing assumption has been that these medications deliver roughly similar results across users. The reality is far messier. Studies have identified specific genetic variants in genes linked to appetite and digestion that directly influence drug effectiveness. People carrying certain variants experience enhanced weight loss; those carrying two copies show even greater results. Researchers have also found that genetic variants associated with stronger weight loss are linked to increased nausea — a side effect that likely contributes to the enhanced effect by suppressing appetite more aggressively.
This isn't just an academic exercise. The variation has real clinical stakes. If a patient's genetics make them a poor responder to semaglutide (Wegovy), they could spend months on an expensive drug that barely moves the needle — when tirzepatide (Mounjaro) or a different intervention might work far better. Right now, prescribing is essentially trial and error. Genetic profiling offers a path toward matching patients with the drug and dose most likely to work for them before they start treatment, not after months of frustration.
Sex, age, and ancestry all factor into the equation. Research shows that women experience greater weight loss on Mounjaro compared to men. Being younger, white, or Asian is also associated with greater response, though the biological mechanisms behind those patterns remain under investigation. Certain genetic variants linked to drug response appear more frequently in people with European ancestry compared to African Americans — a disparity that matters when these drugs are already disproportionately accessed through private online pharmacies. If genetic makeup partly determines who benefits, and the drugs remain unevenly distributed, the gap in real-world outcomes could widen along racial and economic lines. Understanding how individual factors shape health outcomes is becoming more pressing as significant numbers of people turn to these medications.
Studies have also identified genetic variants linked to severe nausea and vomiting on tirzepatide in some users — findings that could eventually help clinicians screen for patients at risk of intolerable side effects. Independent experts rightly note that genetics is only one piece of a complex picture: behavioral factors like exercise, diet, and clinical support remain central drivers of outcomes. And these findings still need replication in larger, more diverse populations before they change clinical practice.
But the direction is clear. The question is no longer whether genetics shapes drug response — it does. The question is how fast the medical system can move from blanket prescriptions to genetically informed ones. That means investing in replication studies, diversifying the populations studied, and building the clinical infrastructure to translate genetic insights into better prescribing decisions. The promise of personalized obesity medicine is real. The gap between that promise and current practice is where patients are losing out.
